|
Name |
Verrucarin J
|
Molecular Formula | C27H32O8 | |
IUPAC Name* |
(1R,3R,8R,12E,18E,20Z,24R,25S,26S)-5,13,25-trimethylspiro[2,10,16,23-tetraoxatetracyclo[22.2.1.03,8.08,25]heptacosa-4,12,18,20-tetraene-26,2'-oxirane]-11,17,22-trione
|
|
SMILES |
CC1=C[C@@H]2[C@@]3(CC1)COC(=O)/C=C(/CCOC(=O)/C=C/C=C\C(=O)O[C@H]4[C@]3([C@]5(CO5)[C@@H](C4)O2)C)\C
|
|
InChI |
InChI=1S/C27H32O8/c1-17-8-10-26-15-32-24(30)13-18(2)9-11-31-22(28)6-4-5-7-23(29)35-19-14-21(34-20(26)12-17)27(16-33-27)25(19,26)3/h4-7,12-13,19-21H,8-11,14-16H2,1-3H3/b6-4+,7-5-,18-13+/t19-,20-,21-,25-,26-,27+/m1/s1
|
|
InChIKey |
GXCGYHWSYNQVHU-GYDJLPFWSA-N
|
|
Synonyms |
Verrucarin J; Muconomycin B; 4643-58-7; 62UBU5Q68G; (1R,3R,8R,12E,18E,20Z,24R,25S,26S)-5,13,25-trimethylspiro[2,10,16,23-tetraoxatetracyclo[22.2.1.03,8.08,25]heptacosa-4,12,18,20-tetraene-26,2'-oxirane]-11,17,22-trione; Verrucarin A, 2',3'-didehydro-2'-deoxy-, (2'E)-; Verrucrin J; Verrucarin J, stereoisomer; VERRUCARIN J [MI]; UNII-62UBU5Q68G; SCHEMBL258631; CHEMBL507752; CHEBI:184115; HY-N10113; 2',3'-Didehydro-2'-deoxyverrucarin A; AI3-29711; CS-0255891; Q27263516
|
|
CAS | 4643-58-7 | |
PubChem CID | 12444784 | |
ChEMBL ID | CHEMBL507752 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 484.5 | ALogp: | 2.5 |
HBD: | 0 | HBA: | 8 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 101.0 | Aromatic Rings: | 5 |
Heavy Atoms: | 35 | QED Weighted: | 0.221 |
Caco-2 Permeability: | -5.211 | MDCK Permeability: | 0.00001730 |
Pgp-inhibitor: | 0.149 | Pgp-substrate: | 0.982 |
Human Intestinal Absorption (HIA): | 0.005 | 20% Bioavailability (F20%): | 0.953 |
30% Bioavailability (F30%): | 0.827 |
Blood-Brain-Barrier Penetration (BBB): | 0.842 | Plasma Protein Binding (PPB): | 82.00% |
Volume Distribution (VD): | 1.352 | Fu: | 9.61% |
CYP1A2-inhibitor: | 0.45 | CYP1A2-substrate: | 0.123 |
CYP2C19-inhibitor: | 0.927 | CYP2C19-substrate: | 0.516 |
CYP2C9-inhibitor: | 0.94 | CYP2C9-substrate: | 0.028 |
CYP2D6-inhibitor: | 0.795 | CYP2D6-substrate: | 0.052 |
CYP3A4-inhibitor: | 0.943 | CYP3A4-substrate: | 0.511 |
Clearance (CL): | 2.899 | Half-life (T1/2): | 0.383 |
hERG Blockers: | 0.158 | Human Hepatotoxicity (H-HT): | 0.619 |
Drug-inuced Liver Injury (DILI): | 0.314 | AMES Toxicity: | 0.815 |
Rat Oral Acute Toxicity: | 0.47 | Maximum Recommended Daily Dose: | 0.955 |
Skin Sensitization: | 0.953 | Carcinogencity: | 0.073 |
Eye Corrosion: | 0.008 | Eye Irritation: | 0.227 |
Respiratory Toxicity: | 0.419 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003126 | 0.763 | D0C7JF | 0.231 | ||||
ENC004774 | 0.752 | D0Q4SD | 0.221 | ||||
ENC002696 | 0.746 | D0G8BV | 0.218 | ||||
ENC003943 | 0.675 | D0Z4ZT | 0.215 | ||||
ENC004775 | 0.672 | D0V4WD | 0.214 | ||||
ENC004446 | 0.606 | D0D2VS | 0.214 | ||||
ENC003173 | 0.586 | D04GJN | 0.212 | ||||
ENC002026 | 0.580 | D0EP0C | 0.209 | ||||
ENC002050 | 0.571 | D09WYX | 0.208 | ||||
ENC003310 | 0.489 | D06XHC | 0.207 |